DE60139244D1 - Kombination von n-acetyl-l-tryptophan mit magnesiurvenschäden - Google Patents

Kombination von n-acetyl-l-tryptophan mit magnesiurvenschäden

Info

Publication number
DE60139244D1
DE60139244D1 DE60139244T DE60139244T DE60139244D1 DE 60139244 D1 DE60139244 D1 DE 60139244D1 DE 60139244 T DE60139244 T DE 60139244T DE 60139244 T DE60139244 T DE 60139244T DE 60139244 D1 DE60139244 D1 DE 60139244D1
Authority
DE
Germany
Prior art keywords
tryptophane
acetyl
magnesium
damage
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60139244T
Other languages
German (de)
English (en)
Inventor
Robert Vink
Alan John James Cook U Nimmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60139244D1 publication Critical patent/DE60139244D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60139244T 2000-01-18 2001-01-18 Kombination von n-acetyl-l-tryptophan mit magnesiurvenschäden Expired - Fee Related DE60139244D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ5146A AUPQ514600A0 (en) 2000-01-18 2000-01-18 Brain injury treatment
PCT/AU2001/000046 WO2001052844A1 (en) 2000-01-18 2001-01-18 Brain, spinal and nerve injury treatment

Publications (1)

Publication Number Publication Date
DE60139244D1 true DE60139244D1 (de) 2009-08-27

Family

ID=3819274

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139244T Expired - Fee Related DE60139244D1 (de) 2000-01-18 2001-01-18 Kombination von n-acetyl-l-tryptophan mit magnesiurvenschäden

Country Status (20)

Country Link
US (5) US6841551B2 (enExample)
EP (1) EP1261335B1 (enExample)
JP (1) JP4794794B2 (enExample)
KR (1) KR100780119B1 (enExample)
CN (1) CN1261095C (enExample)
AU (2) AUPQ514600A0 (enExample)
BR (1) BR0107695A (enExample)
CA (1) CA2397723C (enExample)
CZ (1) CZ20022804A3 (enExample)
DE (1) DE60139244D1 (enExample)
HR (1) HRP20020593B1 (enExample)
HU (1) HUP0301920A3 (enExample)
IL (2) IL150548A0 (enExample)
MX (1) MXPA02007004A (enExample)
NO (1) NO329320B1 (enExample)
NZ (2) NZ519990A (enExample)
RU (1) RU2276996C2 (enExample)
WO (1) WO2001052844A1 (enExample)
YU (1) YU54702A (enExample)
ZA (1) ZA200205715B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
US20060239921A1 (en) 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
US8185176B2 (en) 2005-04-26 2012-05-22 Novadaq Technologies, Inc. Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
WO2007016790A1 (en) * 2005-08-10 2007-02-15 Novadaq Technologies, Inc. Intra-operative head & neck nerve mapping
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
WO2007062060A2 (en) 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US20080161744A1 (en) * 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2010533655A (ja) * 2007-07-19 2010-10-28 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 頭蓋内圧を低下させるための方法
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
EP3372250B1 (en) 2008-05-02 2019-12-25 Novadaq Technologies ULC Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6154135B2 (ja) * 2010-12-03 2017-06-28 国立大学法人 岡山大学 外傷性神経障害治療剤
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP6028096B2 (ja) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド 血管造影及びかん流の定量化並びに解析手法
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
RU2016103099A (ru) * 2013-07-02 2017-08-07 Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
AU2014286926A1 (en) * 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-II
US20160136173A1 (en) * 2013-07-02 2016-05-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
CN107209118B (zh) 2014-09-29 2021-05-28 史赛克欧洲运营有限公司 在自体荧光存在下生物材料中目标荧光团的成像
EP3203902B1 (en) 2014-10-09 2021-07-07 Novadaq Technologies ULC Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
CA3049922A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
WO2021035289A1 (en) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4985896A (en) * 1985-03-29 1991-01-15 Canon Kabushiki Kaisha Laser driving device
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US4981744A (en) * 1990-04-24 1991-01-01 Swank Michael W Non-planar expandable honeycomb structure
AU687754B2 (en) * 1990-08-31 1998-03-05 Warner-Lambert Company Tachykinin antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
WO1997038701A1 (en) * 1996-04-12 1997-10-23 Neotech Medical Innovations In Composition and method for the treatment of premenstrual syndrome
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
EP1017395A4 (en) * 1997-08-28 2003-06-04 Merck & Co Inc Method for treating premenstrual or late luteal phase syndrome
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
KR100437587B1 (ko) 1999-02-24 2004-06-30 에프. 호프만-라 로슈 아게 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
TR200102490T2 (tr) 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6479433B1 (en) 2000-10-02 2002-11-12 Smithers-Oasis Company Polyurethane foam composites for grower applications and related methods

Also Published As

Publication number Publication date
KR100780119B1 (ko) 2007-11-27
PL358251A1 (en) 2004-08-09
YU54702A (sh) 2006-01-16
AU2656001A (en) 2001-07-31
HRP20020593B1 (hr) 2011-03-31
CN1261095C (zh) 2006-06-28
IL150548A0 (en) 2003-02-12
US9186404B2 (en) 2015-11-17
MXPA02007004A (es) 2004-10-15
JP2003520232A (ja) 2003-07-02
AUPQ514600A0 (en) 2000-02-10
US20030109417A1 (en) 2003-06-12
US10201568B2 (en) 2019-02-12
KR20020075784A (ko) 2002-10-05
US6841551B2 (en) 2005-01-11
HRP20020593A2 (en) 2005-10-31
US20090253698A1 (en) 2009-10-08
CZ20022804A3 (cs) 2002-11-13
ZA200205715B (en) 2003-10-17
RU2002121640A (ru) 2004-03-27
NZ534278A (en) 2005-08-26
WO2001052844A1 (en) 2001-07-26
HUP0301920A3 (en) 2010-03-29
JP4794794B2 (ja) 2011-10-19
HK1054872A1 (en) 2003-12-19
EP1261335A1 (en) 2002-12-04
IL150548A (en) 2011-05-31
NO20023423D0 (no) 2002-07-17
RU2276996C2 (ru) 2006-05-27
US20180071333A1 (en) 2018-03-15
EP1261335A4 (en) 2004-09-22
US20160030474A1 (en) 2016-02-04
EP1261335B1 (en) 2009-07-15
NO329320B1 (no) 2010-09-27
AU782799B2 (en) 2005-09-01
NZ519990A (en) 2004-10-29
CA2397723C (en) 2010-08-31
US20050107380A1 (en) 2005-05-19
BR0107695A (pt) 2002-10-15
NO20023423L (no) 2002-09-16
CA2397723A1 (en) 2001-07-26
CN1426302A (zh) 2003-06-25
HUP0301920A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
DE60139244D1 (de) Kombination von n-acetyl-l-tryptophan mit magnesiurvenschäden
DE60112678D1 (de) Direkteinspritzender ottomotor
IS6659A (is) Karvedílól
DE60033639D1 (de) Leuchte
DE60131038D1 (de) Motor-Generator
DE50105915D1 (de) Schutzhülle
DE50101409D1 (de) Reflektor
DE60135144D1 (de) Verbinder
DE60143422D1 (de) Verbinder
DE60116905D1 (de) Beleuchtungsvorrichtungen
DE60102506D1 (de) Verbinder
DE60143985D1 (de) Os
DK1280757T3 (da) Gamma-selektive retinoider
NO20024806D0 (no) Apomorfinderivater samt anvendelse derav
EP1330588A4 (en) Anti bandit shutter
NO20030276L (no) Fremgangsmåte
DE60119875D1 (de) Verbinder
DE50109291D1 (de) Zündverfahren
DE50111451D1 (de) Flache Beleuchtungseinheit
DK1317426T3 (da) Betal-thio-aminosyrer
DE60109670D1 (de) Verbinder
DE60112673D1 (de) Verbinder
DE60143148D1 (de) En mit honigwaben
DE10196460T1 (de) Selbstzerstör-Spritze
DE60100973D1 (de) Verbinder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee